ArticleCancer medicine2025
Heterogeneity of Checkpoint Inhibitor-Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.Journal for immunotherapy of cancer · 2026Article
- Heterogeneity of Checkpoint Inhibitor-Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionCheckpoint inhibitor-associated pneumonitis (CIP) is a serious manifestation following tumor immunotherapy, typically mediated by T lymphocytes. However, the heterogeneity in blood inflammatory profiles and its implications on clinical characteristics and outcomes for CIP remain underexplored.
methodsThis multicenter retrospective study included 113 CIP patients without pathogen infection, aiming to classify CIP based on peripheral blood immune cell percentages.
resultsWe identified three inflammatory subtypes: normal type (42.5%), neutrophil type (41.6%), and eosinophil type (15.9%). The normal-type pneumonitis primarily occurred in Grades 1-2 (79.2%), with nonspecific interstitial pneumonia radiological features, and demonstrated a significant recovery to normal lung status after effective treatment (p < 0.001). In contrast, patients with the neutrophil type were associated with symptomatic onset (p = 0.036), cryptogenic organizing pneumonitis on imaging (p = 0.004), higher steroid doses (> 40 mg/day, p = 0.011), anti-fibrotic treatments (p = 0.007), and pneumonia-related mortality rate was 27.7% (p = 0.037). Eosinophil-type pneumonitis was more common in patients with chronic pulmonary inflammation, typically Grades 1-2 (66.7%) with hypersensitivity pneumonitis patterns (p < 0.001) and better prognosis.
conclusionIn summary, our study reveals that CIP can be classified into normal, neutrophil, and eosinophil types, each with distinct treatment responses and prognoses. These findings underscore the importance of subtype-specific treatment strategies and highlight the prognostic significance of early intervention in both normal and eosinophil subtypes.
trial registrationClinicalTrials.gov identifier: ChiCTR2200065859.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.